Literature DB >> 32493717

In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment.

Heleen Vanhaute1, Jenny Ceccarini2, Laura Michiels2, Michel Koole2, Stefan Sunaert2, Robin Lemmens2, Eric Triau2, Louise Emsell2, Mathieu Vandenbulcke2, Koen Van Laere2.   

Abstract

OBJECTIVE: To investigate in vivo whether synaptic loss and neurofibrillary tangle load spatially overlap and correlate with clinical symptoms in patients with amnestic mild cognitive impairment (aMCI).
METHODS: In this cross-sectional study, 10 patients with aMCI and 10 healthy controls underwent triple PET-MRI with 11C-UCB-J (synaptic vesicle protein 2A), 18F-MK-6240 (tau deposition), and 11C-Pittsburgh compound B (β-amyloid) and neuropsychological assessment. Gray matter atrophy was assessed by voxel-based morphometry with T1-weighted MRIs. Voxel-wise and volume-of-interest analyses were conducted on PET data. The interrelationship of synaptic density and tau deposition was investigated. We also investigated correlations of 18F-MK-6240 and 11C-UCB-J binding with cognitive performance.
RESULTS: Compared to controls, patients with aMCI showed a decreased 11C-UCB-J binding mainly in substructures of the medial temporal lobe (MTL; 48%-51%, p cluster = 0.02). Increased 18F-MK6240 binding in the same region was observed (42%-44%, p cluster = 0.0003), spreading to association cortices. In the MTL, higher 18F-MK-6240 binding inversely related to lower 11C-UCB-J binding (p = 0.02, r = -0.76). Decreased performance on cognitive tests was associated with both increased 18F-MK-6240 and decreased 11C-UCB-J binding in the hippocampus (p < 0.01, r > 0.7), although in a multivariate analysis only 18F-MK-6240 binding was significantly related to cognitive performance.
CONCLUSIONS: Patients with aMCI have high tau deposition and synaptic density loss mainly in key regions known to be involved in early cognitive impairment, indicating that these are interrelated in the MTL, while tau binding had already spread toward association cortices. Longitudinal data are needed to provide further insight into the temporal aspects of this relationship.
© 2020 American Academy of Neurology.

Entities:  

Year:  2020        PMID: 32493717     DOI: 10.1212/WNL.0000000000009818

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

1.  Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern.

Authors:  Greet Vanderlinden; Jenny Ceccarini; Thomas Vande Casteele; Laura Michiels; Robin Lemmens; Eric Triau; Kim Serdons; Jos Tournoy; Michel Koole; Mathieu Vandenbulcke; Koen Van Laere
Journal:  Mol Psychiatry       Date:  2022-07-06       Impact factor: 15.992

2.  Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease.

Authors:  Adam P Mecca; Ming-Kai Chen; Ryan S O'Dell; Mika Naganawa; Takuya Toyonaga; Tyler A Godek; Joanna E Harris; Hugh H Bartlett; Wenzhen Zhao; Emmie R Banks; Gessica S Ni; Kelly Rogers; Jean Dominique Gallezot; Jim Ropchan; Paul R Emery; Nabeel B Nabulsi; Brent C Vander Wyk; Amy F T Arnsten; Yiyun Huang; Richard E Carson; Christopher H van Dyck
Journal:  Neurobiol Aging       Date:  2021-11-20       Impact factor: 4.673

3.  Changes in synaptic density in the subacute phase after ischemic stroke: A 11C-UCB-J PET/MR study.

Authors:  Laura Michiels; Nathalie Mertens; Liselot Thijs; Ahmed Radwan; Stefan Sunaert; Mathieu Vandenbulcke; Geert Verheyden; Michel Koole; Koen Van Laere; Robin Lemmens
Journal:  J Cereb Blood Flow Metab       Date:  2021-09-22       Impact factor: 6.960

4.  In vivo synaptic density relates to glucose metabolism at rest in healthy subjects, but is strongly modulated by regional differences.

Authors:  June van Aalst; Jenny Ceccarini; Stefan Sunaert; Patrick Dupont; Michel Koole; Koen Van Laere
Journal:  J Cereb Blood Flow Metab       Date:  2021-01-14       Impact factor: 6.200

5.  Impact of meningeal uptake and partial volume correction techniques on [18F]MK-6240 binding in aMCI patients and healthy controls.

Authors:  Nathalie Mertens; Laura Michiels; Greet Vanderlinden; Mathieu Vandenbulcke; Robin Lemmens; Koen Van Laere; Michel Koole
Journal:  J Cereb Blood Flow Metab       Date:  2022-01-21       Impact factor: 6.960

6.  In vivo tau pathology is associated with synaptic loss and altered synaptic function.

Authors:  Emma M Coomans; Deborah N Schoonhoven; Hayel Tuncel; Sander C J Verfaillie; Emma E Wolters; Ronald Boellaard; Rik Ossenkoppele; Anouk den Braber; Wiep Scheper; Patrick Schober; Steven P Sweeney; J Michael Ryan; Robert C Schuit; Albert D Windhorst; Frederik Barkhof; Philip Scheltens; Sandeep S V Golla; Arjan Hillebrand; Alida A Gouw; Bart N M van Berckel
Journal:  Alzheimers Res Ther       Date:  2021-02-05       Impact factor: 6.982

Review 7.  Cerebral dysfunctions caused by sepsis during ageing.

Authors:  Tatsuya Manabe; Michael T Heneka
Journal:  Nat Rev Immunol       Date:  2021-11-11       Impact factor: 108.555

8.  Lower synaptic density is associated with psychiatric and cognitive alterations in obesity.

Authors:  Ruth H Asch; Sophie E Holmes; Ania M Jastreboff; Marc N Potenza; Stephen R Baldassarri; Richard E Carson; Robert H Pietrzak; Irina Esterlis
Journal:  Neuropsychopharmacology       Date:  2021-07-22       Impact factor: 7.853

9.  Synaptic density in carriers of C9orf72 mutations: a [11 C]UCB-J PET study.

Authors:  Maura Malpetti; Negin Holland; P Simon Jones; Rong Ye; Thomas E Cope; Tim D Fryer; Young T Hong; George Savulich; Timothy Rittman; Luca Passamonti; Elijah Mak; Franklin I Aigbirhio; John T O'Brien; James B Rowe
Journal:  Ann Clin Transl Neurol       Date:  2021-06-16       Impact factor: 5.430

Review 10.  Protection against Amyloid-β Oligomer Neurotoxicity by Small Molecules with Antioxidative Properties: Potential for the Prevention of Alzheimer's Disease Dementia.

Authors:  Wataru Araki; Fuyuki Kametani
Journal:  Antioxidants (Basel)       Date:  2022-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.